Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
💡 한 문장 핵심
피나스테리드가 전립선암 진단을 위한 PSA 민감도에 미치는 영향.
5/5 보강
TL;DR
The sensitivity of PSA was higher for men in the finasteride group than in the placebo group at all PSA cutoffs matched by specificity, and this bias would be expected to contribute to greater detection of all grades of prostate cancer withfinasteride.
📑 코퍼스 인용 관계
· 인용됨 14
📑 인용한 논문 (6) ▾
- A prospective evaluation of the effect of finasteride on prostate health index (phi). International urology and nephrology · 2023
- Finasteride Counseling for Male Androgenetic Alopecia Should Reflect Updated Findings on P… Skin appendage disorders · 2020
- Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk o… Cancer prevention research (Philadelphia, Pa.) · 2019
- The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on… PloS one · 2018
- Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the P… Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
- The intriguing role of fibroblasts and in the chemopreventive and therapeutic effect of f… Asian journal of andrology · 2016
연도별 인용 (2012–2025) · 합계 161
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Prostate Cancer Treatment and Research
Biological Research and Disease Studies
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
전립선암 예방시험(PCPT)에서 피나스테리드(finasteride)가 전립선암 위험을 낮추면서도 고등급 암 위험은 높이는 역설이 관찰되어, 피나스테리드가 PSA(전립선특이항원)의 암 검출 민감도와 AUC에 미치는 영향을 규명하고자 했습니다.
【방법】
7년간 PCPT에 참여해 전립선 생검과 동시 PSA 검사를 받은 위약군(5,112명)과 피나스테리드군(4,579명)을 대상으로, 전체 전립선암·글리슨 등급(Gleason grade) 7 이상·8 이상 검출에 대한 PSA의 민감도와 AUC를 양군 간 비교했습니다.
【주요 결과】
모든 항목에서 피나스테리드군의 PSA AUC가 위약군보다 높았습니다. 전체 암 검출 AUC는 0.757 대 0.681(P<.001), 글리슨 7 이상은 0.838 대 0.781(P=.003), 글리슨 8 이상은 0.886 대 0.824(P=.071)였으며, 특이도를 맞춘 모든 PSA 절단값에서 피나스테리드군의 민감도가 더 높았습니다.
【임상적 시사점 (성형외과 의사 관점)】
피나스테리드는 남성형 탈모 치료(예: 프로페시아)에 흔히 처방되는데, 본 연구는 이 약물이 PSA의 진단 성능 자체를 변화시킴을 보여줍니다. 따라서 모발 상담 시 복용력을 확인하고, 50세 이상 남성 환자에게 처방·관리할 때는 비뇨기과와 연계해 PSA 수치를 해석(피나스테리드 복용 시 측정값을 약 2배 보정)하도록 안내하는 것이 안전합니다.
[BACKGROUND] In the Prostate Cancer Prevention Trial (PCPT), men receiving finasteride had a 24.8% lower risk of prostate cancer than men receiving placebo but a higher risk of high-grade cancer. We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer.
[METHODS] We studied men in the placebo and finasteride groups of the PCPT who had a prostate biopsy and concurrent PSA tests during the 7-year study. We compared the placebo and finasteride groups for sensitivity and AUC of PSA for the detection of all prostate cancer, of Gleason grade 7 or higher prostate cancer, and of Gleason grade 8 or higher prostate cancer. All statistical tests were two-sided.
[RESULTS] Of 5112 men in the placebo group, prostate cancer was detected in 1111. Gleason tumor grade was available for 1100 men, of whom 240 had grade 7 or higher and 55 had grade 8 or higher. Of 4579 men in the finasteride group, 695 had prostate cancer. Gleason grade was available for 686 men, of whom 264 had grade 7 or higher and 81 had grade 8 or higher. The AUC of PSA for all outcomes was greater for the finasteride group than the placebo group. For detecting prostate cancer versus no cancer, the AUCs were 0.757 and 0.681, respectively (P < .001); for detecting Gleason grade > or = 7 versus < or = 6 or no cancer, the AUCs were 0.838 and 0.781, respectively (P = .003); and for detecting Gleason grade > or = 8 versus < or = 7 or no cancer, the AUCs were 0.886 and 0.824, respectively (P = .071). The sensitivity of PSA was higher for men in the finasteride group than in the placebo group at all PSA cutoffs matched by specificity.
[CONCLUSIONS] PSA had statistically significantly better sensitivity and AUC for detecting prostate cancer in the finasteride arm of the PCPT than in the placebo arm. This bias would be expected to contribute to greater detection of all grades of prostate cancer with finasteride.
[METHODS] We studied men in the placebo and finasteride groups of the PCPT who had a prostate biopsy and concurrent PSA tests during the 7-year study. We compared the placebo and finasteride groups for sensitivity and AUC of PSA for the detection of all prostate cancer, of Gleason grade 7 or higher prostate cancer, and of Gleason grade 8 or higher prostate cancer. All statistical tests were two-sided.
[RESULTS] Of 5112 men in the placebo group, prostate cancer was detected in 1111. Gleason tumor grade was available for 1100 men, of whom 240 had grade 7 or higher and 55 had grade 8 or higher. Of 4579 men in the finasteride group, 695 had prostate cancer. Gleason grade was available for 686 men, of whom 264 had grade 7 or higher and 81 had grade 8 or higher. The AUC of PSA for all outcomes was greater for the finasteride group than the placebo group. For detecting prostate cancer versus no cancer, the AUCs were 0.757 and 0.681, respectively (P < .001); for detecting Gleason grade > or = 7 versus < or = 6 or no cancer, the AUCs were 0.838 and 0.781, respectively (P = .003); and for detecting Gleason grade > or = 8 versus < or = 7 or no cancer, the AUCs were 0.886 and 0.824, respectively (P = .071). The sensitivity of PSA was higher for men in the finasteride group than in the placebo group at all PSA cutoffs matched by specificity.
[CONCLUSIONS] PSA had statistically significantly better sensitivity and AUC for detecting prostate cancer in the finasteride arm of the PCPT than in the placebo arm. This bias would be expected to contribute to greater detection of all grades of prostate cancer with finasteride.
- p-value P < .001
- p-value P = .003
【연구 목적】 전립선암 예방시험(PCPT)에서 피나스테리드(finasteride)가 전립선암 위험을 낮추면서도 고등급 암 위험은 높이는 역설이 관찰되어, 피나스테리드가 PSA(전립선특이항원)의 암 검출 민감도와 AUC에 미치는 영향을 규명하고자 했습니다.
APA 7
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A. (2006). Effect of finasteride on the sensitivity of psa for detecting prostate cancer.. Journal of the National Cancer Institute, 98(16), 1128-33. https://doi.org/10.1093/jnci/djj307
Vancouver
Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Jour. Nati. Canc. Inst.. 2006;98(16):1128-33. doi:10.1093/jnci/djj307
AMA 11
Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Jour. Nati. Canc. Inst.. 2006;98(16):1128-33. doi:10.1093/jnci/djj307
Chicago
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., and Coltman, C. A.. 2006. "Effect of finasteride on the sensitivity of PSA for detecting prostate cancer." Journal of the National Cancer Institute 98 (16): 1128-33. https://doi.org/10.1093/jnci/djj307
MLA 9
Thompson, I. M., et al. "Effect of finasteride on the sensitivity of PSA for detecting prostate cancer." Journal of the National Cancer Institute, vol. 98, no. 16, 2006, pp. 1128-33. doi:10.1093/jnci/djj307.
PMID
16912265 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 14
- Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling appro…
- Finasteride-its impact on sexual function and prostate cancer.
- Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
- Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Ca…
- Does the level of prostate cancer risk affect cancer prevention with finasteride?
- A prospective evaluation of the effect of finasteride on prostate health index (phi).
- The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: R…
- The intriguing role of fibroblasts and in the chemopreventive and therapeutic effect of finasteride…
- Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations w…
- Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the…
- Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer S…
- Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.
- Finasteride Counseling for Male Androgenetic Alopecia Should Reflect Updated Findings on Prostate Ca…
- Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-gra…
같은 제1저자의 인용 많은 논문 (5)
- The influence of finasteride on the development of prostate cancer.
- Long-term survival of participants in the prostate cancer prevention trial.
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
- Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
- Chemoprevention of prostate cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.